|1.||Chou, Kuo-Chen: 3 articles (05/2009 - 08/2003)|
|2.||Wei, Dong-Qing: 3 articles (05/2009 - 08/2003)|
|3.||Gong, Peng: 1 article (12/2014)|
|4.||Sun, Yuna: 1 article (12/2014)|
|5.||Qing, Jie: 1 article (12/2014)|
|6.||Yin, Zheng: 1 article (12/2014)|
|7.||Wang, Yaxin: 1 article (12/2014)|
|8.||Cao, Lin: 1 article (12/2014)|
|9.||Shu, Bo: 1 article (12/2014)|
|10.||Lou, Zhiyong: 1 article (12/2014)|
03/01/2013 - "In conclusion, we established that rupintrivir can strongly contain the spread of EV71 infection in vivo at a clinically acceptable dose (as low as 0.1mg/kg). "
03/01/2013 - "Rupintrivir is a promising candidate for treating severe cases of enterovirus-71 infection: evaluation of antiviral efficacy in a murine infection model."
01/14/2010 - "Rupintrivir, whose safety profiles had been proved, is an attractive candidate and can be quickly utilized for treating severe EV71 infection."
01/14/2010 - "Rupintrivir is a promising candidate for treating severe cases of Enterovirus-71 infection."
10/01/1999 - "In a single-cycle, time-of-addition assay, AG7088 demonstrated antiviral activity when added up to 6 h after infection. "
|3.||Severe Acute Respiratory Syndrome
08/15/2003 - "In order to stimulate the development of drugs against severe acute respiratory syndrome (SARS), based on the atomic coordinates of the SARS coronavirus main proteinase determined recently [Science 13 (May) (2003) (online)], studies of docking KZ7088 (a derivative of AG7088) and the AVLQSGFR octapeptide to the enzyme were conducted. "
05/01/2004 - "To stimulate the structure-based drug design against SARS (severe acute respiratory syndrome), a pharmacophore search was conducted over 3.6 millions of compounds based on the atomic coordinates of the complex obtained by docking KZ7088 (a derivative of AG7088) to SARS CoV M(pro) (coronavirus main proteinase), as reportedly recently (Chou, K. "
11/01/2000 - "Pfizer (formerly Agouron) is developing AG-7088, a peptide aldehyde that targets the human rhinovirus (HRV) 3C proteinase enzyme and has potential for the treatment of the common cold. "
09/01/2000 - "We tested the in vitro activity of pleconaril and AG7088 against five numbered human rhinovirus (HRV) serotypes and 46 clinical HRV isolates of undefined serotype recovered from patients with common colds. "
05/01/2002 - "However, AG7088 (1) an inhibitor of rhinovirus-3C is in phase II/III clinical trial for the treatment of common cold and VX-740 (2, pralnacasan) an inhibitor of caspase-1 is in phase II clinical trial as an anti-inflammatory agent for rheumatoid arthritis. "
07/01/2005 - "Rupintrivir, also known as AG7088, is a small molecule 3C protease inhibitor designed to target human rhinovirus as a potential intranasal treatment for the common cold. "
|5.||Myositis (Idiopathic Inflammatory Myopathies)
|1.||Dimethyl Sulfoxide (DMSO)
|2.||Interleukin-8 (Interleukin 8)
|3.||Interleukin-6 (Interleukin 6)
|5.||Protease Inhibitors (Protease Inhibitor)